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Chronic graft-versus-host disease (CGVHD) is a complication that may arise in patients who have 
received bone marrow or stem cell transplants from another person (allogeneic transplants), in which 
the transplanted immune cells attack the host's own cells. Compared with acute GVHD, the chronic 
form usually occurs later, normally after 100 days post-transplant, and lasts longer, and it is the 
leading cause of late morbidity and mortality among recipients of allogeneic hematopoietic cell 
transplantation (HCT). 
In 2011, a risk score was developed for patients with CGVHD in a study from the Center for 
International Bone Marrow Transplant Research (CIBMTR) that included a number of Fred Hutch 
investigators. CIBMTR is a voluntary research organization that involves more than 500 
transplantation centers that have agreed to share patient data and collaborate in scientific studies. 
Using multivariate analysis of a cohort of 5343 CGVHD patients, ten significant variables were 
successfully identified for predicting the overall survival and non-relapse mortality; the latter defined 
as death in continuous remission (Arora et al., 2011). The variables were age, prior acute GVHD, 
time from HCT to CGVHD, donor type, disease status at transplantation, GVHD prophylaxis, gender 
mismatch, serum total bilirubin, Karnofsky performance status (the ability to perform ordinary, daily 
activities on a scale from 0 to 100) and platelet count at the time of CGVHD diagnosis. The study 
concluded that patients could be categorized into six well-defined risk groups that adequately 
reflected the assessed outcomes, but to advance from "promising" to clinically useful the score 
needed to be validated in an independent dataset. 
To determine the reproducibility of the risk scores developed in the earlier study, the researchers 
followed up by identifying a new set of 1128 CGVHD patients that received HCT between 2005 and 
2007, and applied the same inclusion criteria and risk-score calculations. In both studies, all patients 
were registered with CIBMTR. Some discrepancies were seen between the validation cohort and the 
training cohort; most importantly, the proportion of patients assigned to the various risk groups 
differed considerably. The proportion of patients in risk groups 1 and 2 (lowest risk) were significantly 
higher in the validation study, and no patients qualified for groups 5 or 6 (highest risk). Only 12% of 
all patients in the validation cohort were assigned risk group 3 or 4, and the two groups were 
therefore combined; the final comparison was consequently carried out in three separate risk groups  
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(RG1 = lowest risk, RG2 = intermediate, RG3 = highest). The disparity between the two patient 
cohorts was likely due to uniquely different baseline characteristics; nevertheless, good 
discriminatory ability was demonstrated for the CIBMTR CGVHD risk score in predicting overall 
survival and non-relapse mortality in patients with CGVHD. Simply put, better survival was seen in 
patients with a lower risk score (< RG3) than in those with a higher risk score. 
The results of this validation study were recently published in Biology of Blood and Marrow 
Transplantation, with Dr. Mary Flowers as the senior and corresponding author. Dr. Flowers is the 
director of the Adult Clinical Service Long-Term Follow-Up Program (LTFU) at Fred Hutch and 
Seattle Cancer Care Alliance. Although the lower rate of patients assigned to the highest risk groups 
(RG4 to RG6) has yet to be fully explained, another study by Dr. Flowers and colleagues described 
comparable findings when evaluating the score in patients diagnosed using the National Institutes of 
Health (NIH) consensus criteria for GVHD (Inamoto et al., 2014). 
"The CIBMTR risk score performed well in predicting differences in overall survival also when 
applied in other cohorts treated for NIH chronic GVHD in two individual centers," Dr. Flowers said, 
adding that, "Of interest, lower non-relapse mortality was observed in patients with more risk factors 
(> group 3) at the Fred Hutch cohort compared to the Princess Margaret Hospital (Toronto, ON, 
Canada) and the CIBMTR cohort. The dedicated long-term follow up program at Fred Hutch may 
have contributed to the superior outcome noted in this high-risk group." 
And there is more good news for the transplantation community; according to Dr. Flowers, the 
validated risk score can be readily introduced in the clinic: "The CIBMTR CGVHD score is easy to 
apply and can be used for prediction of major outcomes, treatment planning and enrollment in 
clinical trials." Another handy tool for improving the care of cancer patients. 
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Image provided by Dr. Mary Flowers 
Kaplan-Meier curves showing overall survival and non-
relapse mortality (NRM) among patients with chronic graft-
versus-host disease (CGVHD) according to CIBMTR risk 
score (n = 1128). 
 
